将来的には、手術前に患者のiPS細胞から輸血用の血小板を作ることも可能になるという。12日に開かれる米国血液学会で発表する。
研究所の江藤教授らは、iPS細胞の作製に使われる遺伝子の一つに、血小板を作る血液細胞「巨核球」を増やす働きがあることに着目。iPS細
胞を巨核球に変化させる過程で、この遺伝子と、細胞増殖を助ける別の遺伝子を細胞核に組み込み、さらに、この二つの遺伝子を活性化させる薬剤を加えて巨核球を大量に増やした。マウス実験で、巨核球からできた血小板が傷口に集まり、止血することも確認した。医学の進歩は凄いですね。近い将来再生医療が当たり前の時代になっているのかもしれませんね。Human iPS cells can change into cells of all tissues and organs (the new iPS cells) from a method of producing large amounts of platelet hemostatic effect, developed by the Institute of Kyoto University iPS cells.
In the future, it becomes possible to create iPS cells and platelets for transfusion from the patient prior to surgery. Presented at the American Society of Hematology to be held on April 12.
Prof. Eto of the Institute, one of the genes in the cells used to create iPS, produce blood cells and platelets 'megakaryocytes' attention that there is work to increase. In the process of changing into megakaryocytes cells iPS, and this gene incorporated into the cell nucleus to another gene helps cell growth, further increased the large number of megakaryocytes in addition to drugs that activate genes of the two. In mouse experiments, we gather from megakaryocytes and platelets in the wound, was also confirmed that the bleeding. Medical progress is incredible. I might have become commonplace in the era of regenerative medicine in the near future.
0 件のコメント:
コメントを投稿